🕒 Thursday 15 May 2025 Thu, 15 May 2025

GPT Group and QuadReal Property Group have partnered to create a $1 billion logistics joint venture focused on Australia's east coast, aiming to expand their footprint in stabilised and core plus logistics assets.

Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.

Heavy Minerals Limited attributes its recent share price jump to media coverage about its upcoming Port Gregory Pre-Feasibility Study and confirms compliance with ASX disclosure rules.

National Australia Bank has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.85 per share for the half-year ending March 2025, payable in multiple currencies.

Classic Minerals Limited has announced the resignation of CEO Dean Goodwin, effective April 7, 2025, with Chair John Lester stepping in as interim leader. The delayed disclosure raises questions about governance timing.

Capricorn Metals announces the dismissal of charges against CEO Paul Criddle, who has resigned to focus on personal priorities. Executive Chairman Mark Clark takes over CEO duties, with plans to re-engage Criddle in a senior project role.

Tempest Minerals reports promising initial metallurgical results from its Remorse Iron discovery in Western Australia, highlighting high-grade iron concentrate with low impurities. Further test results are anticipated, underpinning ongoing project development.

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Sigma Healthcare has released its standalone annual and sustainability reports for the year ending January 2025, marking the final disclosures before its merger with Chemist Warehouse Group in February 2025.

Wingara AG Limited’s planned funding placement with Terra Firma Equity Limited has fallen through, prompting legal considerations and a pause on a key board appointment.

Chimeric Therapeutics reports encouraging interim results from its ADVENT-AML Phase 1B trial, with two of three newly diagnosed AML patients achieving remission using their novel CORE-NK cell therapy combined with standard treatment.

Mineral Commodities Ltd reveals ongoing delays in completing the sale of its Skaland Graphite Project due to funding issues faced by the buyer, Norge Mineraler. Despite partial payments and new guarantees, the final USD 9.62 million payment remains outstanding.

Bass Limited’s May 2025 AGM update highlights a strategic acquisition and capital raising to accelerate its emergence as a key Australian gas producer, focusing on Cooper Basin and Indonesian assets.

Ava Risk Group has landed a $1.1 million contract to deploy its advanced fibre sensing technology at a major ADNOC oil and gas field in Abu Dhabi, reinforcing its strategic partnership with Honeywell and its foothold in critical infrastructure security.

Epsilon Healthcare has launched a $1 million loan note issue aimed at supporting its working capital and diversification efforts, with a 10% interest rate and potential share conversion.

Embark Early Education announces a fully franked interim dividend and the conditional acquisition of two Queensland childcare centres, boosting its portfolio to 40 centres.

Garda Property Group has upgraded its FY25 Funds from Operations guidance by 12%, maintaining distributions while preparing for the North Lakes sale settlement in August 2025. The sale proceeds will significantly reduce gearing, with capital gains tax implications deferred to FY26.

Aspen Group has launched a $74 million equity raising to reduce debt and capitalize on growth opportunities in affordable housing, maintaining its FY25 earnings guidance.

Aspen Group announces a $74 million equity raise alongside robust earnings growth and unchanged FY25 guidance, positioning itself for expansion in Australia’s tight housing market.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Southern Cross Gold has successfully closed the second tranche of its C$143 million private placement, securing nearly C$30 million to fund critical milestones at its Sunday Creek Gold-Antimony Project in Australia.

Peak Rare Earths is poised for acquisition by Shenghe Resources in a deal valuing the company at A$150.5 million, supported by a A$7.5 million entitlement offer to fund ongoing development and transaction costs.

Navigator Global Investments has raised its FY25 earnings outlook, projecting a 17-22% increase in adjusted EBITDA driven by robust profit distributions from its diversified Partner Firms.

Peak Rare Earths Limited has agreed to be acquired by Ganzhou Chenguang Rare Earths New Material Co., Ltd., a subsidiary of Shenghe Resources, in a deal valuing Peak at A$150.5 million plus proceeds from a proposed entitlement offer. The transaction offers Peak shareholders a significant premium and aims to accelerate development of the Ngualla Rare Earth Project.